Abstract
Evidence implicating neural circuits that utilize the neuropeptide transmitter neurotensin (NT) in the pathophysiology of schizophrenia and in the mechanism of action of antipsychotic drugs has previously been reviewed. The majority of evidence, taken together, supports the development of NT receptor agonists as novel antipsychotic drugs. This review comprehensively describes the NT receptor subtypes, discusses the development of NT receptor agonists and the behavioral effects of currently available NT receptor agonists. The compilation of data suggests that NT receptor agonists may represent a novel class of antipsychotic drugs for the treatment of schizophrenia.
Keywords: Antipsychotic drug, peptide, neuromedin N, xenin, schizophrenia
CNS & Neurological Disorders - Drug Targets
Title: Novel Treatments of Schizophrenia: Targeting the Neurotensin System
Volume: 5 Issue: 2
Author(s): B. Kinkead and C. B. Nemeroff
Affiliation:
Keywords: Antipsychotic drug, peptide, neuromedin N, xenin, schizophrenia
Abstract: Evidence implicating neural circuits that utilize the neuropeptide transmitter neurotensin (NT) in the pathophysiology of schizophrenia and in the mechanism of action of antipsychotic drugs has previously been reviewed. The majority of evidence, taken together, supports the development of NT receptor agonists as novel antipsychotic drugs. This review comprehensively describes the NT receptor subtypes, discusses the development of NT receptor agonists and the behavioral effects of currently available NT receptor agonists. The compilation of data suggests that NT receptor agonists may represent a novel class of antipsychotic drugs for the treatment of schizophrenia.
Export Options
About this article
Cite this article as:
Kinkead B. and Nemeroff B. C., Novel Treatments of Schizophrenia: Targeting the Neurotensin System, CNS & Neurological Disorders - Drug Targets 2006; 5 (2) . https://dx.doi.org/10.2174/187152706776359655
DOI https://dx.doi.org/10.2174/187152706776359655 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review of Current Drug Targets and Pharmacology of Antipsychotic Treatment
Medicinal Chemistry Reviews - Online (Discontinued) Adenosine A2A Receptor Antagonists and Parkinsons Disease: State of the Art and Future Directions
Current Pharmaceutical Design Biomarker Metabolite Signatures Pave the Way for Electronic-nose Applications in Early Clinical Disease Diagnoses
Current Metabolomics Noradrenaline in Parkinsons Disease: From Disease Progression to Current Therapeutics
Current Medicinal Chemistry BDNF Serum Concentrations Show No Relationship with Diagnostic Group or Medication Status in Neurodegenerative Disease
Current Alzheimer Research Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology Excitotoxic Mechanisms in Non-Motor Dysfunctions and Levodopa- Induced Dyskinesia in Parkinson's Disease: The Role of the Interaction Between the Dopaminergic and the Kynurenine System
Current Medicinal Chemistry Behavioural Sensitisation During Dopamine Replacement Therapy in Parkinsons Disease is Reminiscent of the Addicted Brain
Current Topics in Medicinal Chemistry Endocannabinoid System: Emerging Role from Neurodevelopment to Neurodegeneration
Mini-Reviews in Medicinal Chemistry Monoamine Oxidase B Inhibitors in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Trends and Applications of Brain Computer Interfaces
Current Signal Transduction Therapy Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives
CNS & Neurological Disorders - Drug Targets Schizophrenia: From Dopamine to Glutamate and Back
Current Medicinal Chemistry Dopamine Receptor Pharmacology: Interactions with Serotonin Receptors and Significance for the Aetiology and Treatment of Schizophrenia
CNS & Neurological Disorders - Drug Targets Bitropic D3 Dopamine Receptor Selective Compounds s Potential Antipsychotics
Current Pharmaceutical Design Current Limitations in the Treatment of Parkinson’s and Alzheimer’s Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers
Current Medicinal Chemistry Adenosine Receptor Ligands in Clinical Trials
Current Topics in Medicinal Chemistry The Use of Stem Cells in Regenerative Medicine for Parkinson’s and Huntington’s Diseases
Current Medicinal Chemistry Do Adult Stem Cells Ameliorate the Damaged Myocardium? Human Cord Blood as a Potential Source of Stem Cells
Current Vascular Pharmacology Selected Natural and Synthetic Agents Effective against Parkinson’s Disease with Diverse Mechanisms
Current Topics in Medicinal Chemistry